189 related articles for article (PubMed ID: 14664896)
1. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase.
Böger RH; Vallance P; Cooke JP
Atheroscler Suppl; 2003 Dec; 4(4):1-3. PubMed ID: 14664896
[No Abstract] [Full Text] [Related]
2. ADMA and oxidative stress.
Sydow K; Münzel T
Atheroscler Suppl; 2003 Dec; 4(4):41-51. PubMed ID: 14664902
[TBL] [Abstract][Full Text] [Related]
3. The DDAH/ADMA/NOS pathway.
Tran CT; Leiper JM; Vallance P
Atheroscler Suppl; 2003 Dec; 4(4):33-40. PubMed ID: 14664901
[TBL] [Abstract][Full Text] [Related]
4. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.
Lentz SR; Rodionov RN; Dayal S
Atheroscler Suppl; 2003 Dec; 4(4):61-5. PubMed ID: 14664904
[TBL] [Abstract][Full Text] [Related]
5. ADMA and hyperhomocysteinemia.
Dayal S; Lentz SR
Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
[TBL] [Abstract][Full Text] [Related]
6. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
Sydow K; Hornig B; Arakawa N; Bode-Böger SM; Tsikas D; Münzel T; Böger RH
Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698
[TBL] [Abstract][Full Text] [Related]
7. The DDAH-ADMA-NOS pathway.
Leiper JM
Ther Drug Monit; 2005 Dec; 27(6):744-6. PubMed ID: 16404814
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
Böger RH
J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.
Vallance P; Leiper J
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1023-30. PubMed ID: 15105281
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric dimethylarginine: clinical applications in pediatric medicine.
Tain YL; Huang LT
J Formos Med Assoc; 2011 Feb; 110(2):70-7. PubMed ID: 21377060
[TBL] [Abstract][Full Text] [Related]
12. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease.
Böger RH; Zoccali C
Atheroscler Suppl; 2003 Dec; 4(4):23-8. PubMed ID: 14664899
[TBL] [Abstract][Full Text] [Related]
13. Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects.
Cable DG; Celotto AC; Evora PR; Schaff HV
Med Sci Monit; 2009 Sep; 15(9):BR248-53. PubMed ID: 19721392
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
Böger RH
Vasc Med; 2005 Jul; 10 Suppl 1():S19-25. PubMed ID: 16444865
[TBL] [Abstract][Full Text] [Related]
15. The clinical significance of asymmetric dimethylarginine.
Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
[TBL] [Abstract][Full Text] [Related]
16. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
[TBL] [Abstract][Full Text] [Related]
18. ADMA: its role in vascular disease.
Cooke JP
Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864
[TBL] [Abstract][Full Text] [Related]
19. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.
Sydow K; Mondon CE; Cooke JP
Vasc Med; 2005 Jul; 10 Suppl 1():S35-43. PubMed ID: 16444867
[TBL] [Abstract][Full Text] [Related]
20. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
